In vivo imaging of astrocytosis in Alzheimer's disease: an (11)C-L: -deuteriodeprenyl and PIB PET study.

Research output: Contribution to journalArticle

Standard

In vivo imaging of astrocytosis in Alzheimer's disease: an (11)C-L: -deuteriodeprenyl and PIB PET study. / Santillo, Alexander; Gambini, Juan Pablo; Lannfelt, Lars; Långström, Bengt; Luohija, Ulla-Maja; Kilander, Lena; Engler, Henry.

In: European Journal of Nuclear Medicine and Molecular Imaging, Vol. 38, No. 12, 2011, p. 2202-2208.

Research output: Contribution to journalArticle

Harvard

APA

CBE

MLA

Vancouver

Author

Santillo, Alexander ; Gambini, Juan Pablo ; Lannfelt, Lars ; Långström, Bengt ; Luohija, Ulla-Maja ; Kilander, Lena ; Engler, Henry. / In vivo imaging of astrocytosis in Alzheimer's disease: an (11)C-L: -deuteriodeprenyl and PIB PET study. In: European Journal of Nuclear Medicine and Molecular Imaging. 2011 ; Vol. 38, No. 12. pp. 2202-2208.

RIS

TY - JOUR

T1 - In vivo imaging of astrocytosis in Alzheimer's disease: an (11)C-L: -deuteriodeprenyl and PIB PET study.

AU - Santillo, Alexander

AU - Gambini, Juan Pablo

AU - Lannfelt, Lars

AU - Långström, Bengt

AU - Luohija, Ulla-Maja

AU - Kilander, Lena

AU - Engler, Henry

N1 - The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Department of Psychogeriatrics (013304000)

PY - 2011

Y1 - 2011

N2 - PURPOSE: Astrocytosis is an important feature of the neuropathology of Alzheimer's disease (AD), yet there is currently no way of detecting this phenomenon in vivo. METHODS: In this study we examine the retention of the positron emission tomography (PET) tracer (11)C-L: -deuteriodeprenyl (DED), thought to bind activated astrocytes, in 9 patients with moderate to severe AD compared with 11 healthy controls. As a measure of amyloid load, (11)C-labelled Pittsburgh Compound B (PIB) retention was determined. RESULTS: Results show a significantly higher (11)C-L: -DED retention in the frontal (35.1% increase, p = 0.001), parietal (35.2%, p = 0.001), temporal (30.9%, p = 0.0001) and medial temporal lobes (22.3%, p = 0.001) in AD compared to healthy controls after blood flow correction. DED retention in the sensorimotor and occipital cortices, and in white matter and subcortical structures, did not differ between groups. There was a moderate but statistically significant (r = 0.492, p = 0.01) correlation between DED and PIB retention values. CONCLUSION: Our conclusion is that DED may serve as an in vivo marker for astrocytosis in AD, providing a window into intermediate processes between amyloidosis and neuronal loss and a means of monitoring immunotherapy.

AB - PURPOSE: Astrocytosis is an important feature of the neuropathology of Alzheimer's disease (AD), yet there is currently no way of detecting this phenomenon in vivo. METHODS: In this study we examine the retention of the positron emission tomography (PET) tracer (11)C-L: -deuteriodeprenyl (DED), thought to bind activated astrocytes, in 9 patients with moderate to severe AD compared with 11 healthy controls. As a measure of amyloid load, (11)C-labelled Pittsburgh Compound B (PIB) retention was determined. RESULTS: Results show a significantly higher (11)C-L: -DED retention in the frontal (35.1% increase, p = 0.001), parietal (35.2%, p = 0.001), temporal (30.9%, p = 0.0001) and medial temporal lobes (22.3%, p = 0.001) in AD compared to healthy controls after blood flow correction. DED retention in the sensorimotor and occipital cortices, and in white matter and subcortical structures, did not differ between groups. There was a moderate but statistically significant (r = 0.492, p = 0.01) correlation between DED and PIB retention values. CONCLUSION: Our conclusion is that DED may serve as an in vivo marker for astrocytosis in AD, providing a window into intermediate processes between amyloidosis and neuronal loss and a means of monitoring immunotherapy.

KW - Pittsburgh Compound B

KW - C-11-L-deuteriodeprenyl

KW - Astrocytosis

KW - Alzheimer's disease

KW - Positron emission tomography

U2 - 10.1007/s00259-011-1895-9

DO - 10.1007/s00259-011-1895-9

M3 - Article

VL - 38

SP - 2202

EP - 2208

JO - European Journal of Nuclear Medicine and Molecular Imaging

T2 - European Journal of Nuclear Medicine and Molecular Imaging

JF - European Journal of Nuclear Medicine and Molecular Imaging

SN - 1619-7070

IS - 12

ER -